Wenxiong Xu

Prof. Dr. Wenxiong Xu

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
DCDabiao Chen
Dabiao Chen
WXWenxiong Xu
Wenxiong Xu
ZLZiying Lei
Ziying Lei
ZHZhanlian Huang
Zhanlian Huang
JLJing Liu
Jing Liu
LPLiang Peng
Liang Peng
The ongoing outbreak of COVID-19 that began in Wuhan, China, has constituted a Public Health Emergency of International Concern, with cases confirmed in multiple countries. Currently, patients are the primary source of infection. We report a confirmed case of COVID-19 whose oropharyngeal swab test of SARS-CoV-2 RNA turned positive in convalescence. This case highlights the importance of active surveillance of SARS-CoV-2 RNA for infectivity assessment.

5 August 2020 in Cell Research
Verified
Journal Article
Open access
PDF file
KYKuai Yu
Kuai Yu
JHJingjing He
Jingjing He
YWYongjian Wu
Yongjian Wu
BXBaosong Xie
Baosong Xie
XLXuefei Liu
Xuefei Liu
PZPenghui Zhou
Penghui Zhou

1 May 2020 in Travel Medicine and Infectious Disease
Verified
Journal Article
Open access
ZLZiying Lei
Ziying Lei
HCHuijuan Cao
Huijuan Cao
YJYusheng Jie
Yusheng Jie
ZHZhanlian Huang
Zhanlian Huang
XGXiaoyan Guo
Xiaoyan Guo
BLBing-Liang Lin
Bing-Liang Lin
Coronavirus disease 2019 (COVID-19) has spread outside the initial epicenter of Wuhan. We compared cases in Guangzhou and Wuhan to illustrate potential changes in pathogenicity and epidemiological characteristics as the epidemic has progressed. We studied 20 patients admitted to the Third Affiliated Hospital of Sun Yat-Sen University in Guangzhou, China from January 22 to February 12, 2020. Data were extracted from medical records. These cases were compared with the 99 cases, previously published in Lancet, from Wuhan Jinyintan Hospital from January 1 to January 20, 2020. Guangzhou patients were younger and had better prognosis than Wuhan patients. The Wuhan patients were more likely to be admitted to the ICU (23% vs 5%) and had a higher mortality rate (11% vs 0%). Cases in Guangzhou tended to be more community clustered. Diarrhea and vomiting were more common among Guangzhou patients and SARS-CoV-2 RNA was found in feces. Fecal SARA-CoV-2 RNA remained positive when nasopharyngeal swabs turned negative in some patients. This study indicates possible diminishing virulence of the virus in the process of transmission. Yet persistent positive RNA in feces after negative nasopharyngeal swabs suggests a possible prolonged transmission period that challenges current quarantine practices.

4 February 2019 in Stem Cells International
Verified
Journal Article
Open access
PDF file
WXWenxiong Xu
Wenxiong Xu
HHHong-Liang He
Hong-Liang He
SPShun-Wen Pan
Shun-Wen Pan
YCYuan-Li Chen
Yuan-Li Chen
MZMei-Ling Zhang
Mei-Ling Zhang
JLJianguo Li
Jianguo Li
Background. Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a common type of liver failure with a high mortality. This study aimed at investigating the safety and efficacy of the combination treatment of plasma exchange (PE) and umbilical cord-derived mesenchymal stem cell (UC-MSCs) transplantation for HBV-ACLF patients.Methods. A total of 110 HBV-ACLF patients treated in our hospital from January 2012 to September 2017 were enrolled into this trial and divided into the control group (n=30), UC-MSC group (n=30), PE group (n=30), and UC-MSC + PE group (n=20) based on their treatments. The hepatic function, coagulation, and virological and immunological markers were assessed at baseline and 30, 60, 90, 180, and 360 days. The endpoint outcomes were death and unfavorable outcome (need for liver transplantation or death).Results. The UC-MSC + PE group had the lowest rates of death and unfavorable outcome at 30 days, 60 days, and 90 days posttreatment among the four groups, but the difference did not reach significances. The multivariate logistic regression analysis demonstrated that hemoglobin, prothrombin activity, and MELD (model for end-stage liver disease) score were the independent factors associated with the unfavorable outcome (allP<0.05). The levels of total bilirubin, alanine aminotransferase, aspartate transaminase, and MELD score were significantly decreased during treatments (allP<0.05).Conclusion. UC-MSCs combined with PE treatment had good safety but cannot significantly improve the short-term prognosis of HBV-ACLF patients with as compared with the single treatment. The long-term efficacy should be further evaluated. This trial is registered with registration no.NCT01724398.

20 March 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JGJiao Gong
Jiao Gong
JOJingyi Ou
Jingyi Ou
XQXueping Qiu
Xueping Qiu
YJYusheng Jie
Yusheng Jie
YCYaqiong Chen
Yaqiong Chen
BHBo Hu
Bo Hu
Background: Due to no reliable risk stratification tool for severe corona virus disease 2019 (COVID-19) patients at admission, we aimed to construct an effective model for early identifying cases at high risk of progression to severe COVID-19. Methods: In this retrospective three-centers study, 372 non-severe COVID-19 patients during hospitalization were followed for more than 15 days after admission. Patients who deteriorated to severe or critical COVID-19 and patients who kept non-severe state were assigned to the severe and non-severe group, respectively. Based on baseline data of the two groups, we constructed a risk prediction nomogram for severe COVID-19 and evaluate its performance. Results: The train cohort consisted of 189 patients, while the two independent validation cohorts consisted of 165 and 18 patients. Among all cases, 72 (19.35%) patients developed severe COVID-19. We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19. We generated the nomogram for early identifying severe COVID-19 in the train cohort (AUC 0.912 [95% CI 0.846-0.978], sensitivity 85.71%, specificity 87.58%); in validation cohort (0.853 [0.790-0.916], 77.5%, 78.4%). The calibration curve for probability of severe COVID-19 showed optimal agreement between prediction by nomogram and actual observation. Decision curve and clinical impact curve analysis indicated that nomogram conferred high clinical net benefit. Conclusion: Our nomogram could help clinicians to early identify patients who will exacerbate to severe COVID-19, which will enable better centralized management and early treatment of severe patients. Summary: Older age; higher LDH, CRP, RDW, DBIL, BUN; lower ALB on admission correlated with higher odds of severe COVID-19. An effective prognostic nomogram composed of 7 features could allow early identification of patients at risk of exacerbation to severe COVID-19.

25 February 2020 in medRxiv
Verified
Preprint
Open access
PDF file
LPLiang Peng
Liang Peng
JLJing Liu
Jing Liu
WXWenxiong Xu
Wenxiong Xu
QLQiumin Luo
Qiumin Luo
KDKeji Deng
Keji Deng
ZGZhi-Liang Gao
Zhi-Liang Gao
We tested samples collected from nine patients diagnosed with coronavirus disease 2019 (COVID-19). The virus was found in urine, blood, anal swabs and oropharyngeal swabs. It is the first time for SARS-CoV-2 found in urine, though no urinary irritation was found.